恒瑞医药(600276.SH)：注射用瑞康曲妥珠单抗临床试验获批准

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of injection drug Rukang Qutuzumab in patients with HER2-positive solid tumors [1] Group 1 - The approval allows for the clinical trial of Rukang Qutuzumab as a monotherapy [1] - The focus of the trial is on patients with HER2 amplification in solid tumors [1]